About MAX gene-associated protein
MAX gene-associated protein (MGA) is a protein
from Homo sapiens identified by UniProt accession
Q8IWI9, 3065 residues long.
MolForge cross-references it against 0 known binders and
51 disease associations.
Target properties
| Protein name | MAX gene-associated protein |
|---|
| UniProt accession | Q8IWI9 |
|---|
| Gene | MGA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 3065 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (51)
Diseases linked to this target (Open Targets).
- chronic lymphocytic leukemia · score 0.37
- lean body mass · score 0.36
- lung adenocarcinoma · score 0.35
- fat body mass · score 0.33
- prostate adenocarcinoma · score 0.32
- non-small cell lung carcinoma · score 0.31
- Pleural Mesothelioma · score 0.30
- whole body water mass · score 0.26
- multiple myeloma · score 0.26
- body weight · score 0.24
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (3065 residues)
MEEKQQIILA NQDGGTVAGA APTFFVILKQ PGNGKTDQGI LVTNQDACAL ASSVSSPVKS KGKICLPADC TVGGITVTLD NNSMWNEFYH RSTEMILTKQ GRRMFPYCRY WITGLDSNLK YILVMDISPV DNHRYKWNGR WWEPSGKAEP HVLGRVFIHP ESPSTGHYWM HQPVSFYKLK LTNNTLDQEG HIILHSMHRY LPRLHLVPAE KAVEVIQLNG PGVHTFTFPQ TEFFAVTAYQ NIQITQLKID YNPFAKGFRD DGLNNKPQRD GKQKNSSDQE GNNISSSSGH RVRLTEGQGS EIQPGDLDPL SRGHETSGKG LEKTSLNIKR DFLGFMDTDS ALSEVPQLKQ EISECLIASS FEDDSRVASP LDQNGSFNVV IKEEPLDDYD YELGECPEGV TVKQEETDEE TDVYSNSDDD PILEKQLKRH NKVDNPEADH LSSKWLPSSP SGVAKAKMFK LDTGKMPVVY LEPCAVTRST VKISELPDNM LSTSRKDKSS MLAELEYLPT YIENSNETAF CLGKESENGL RKHSPDLRVV QKYPLLKEPQ WKYPDISDSI STERILDDSK DSVGDSLSGK EDLGRKRTTM LKIATAAKVV NANQNASPNV PGKRGRPRKL KLCKAGRPPK NTGKSLISTK NTPVSPGSTF PDVKPDLEDV DGVLFVSFES KEALDIHAVD GTTEESSSLQ ASTTNDSGYR ARISQLEKEL IEDLKTLRHK QVIHPGLQEV GLKLNSVDPT MSIDLKYLGV QLPLAPATSF PFWNLTGTNP ASPDAGFPFV SRTGKTNDFT KIKGWRGKFH SASASRNEGG NSESSLKNRS AFCSDKLDEY LENEGKLMET SMGFSSNAPT SPVVYQLPTK STSYVRTLDS VLKKQSTISP STSYSLKPHS VPPVSRKAKS QNRQATFSGR TKSSYKSILP YPVSPKQKYS HVILGDKVTK NSSGIISENQ ANNFVVPTLD ENIFPKQISL RQAQQQQQQQ QGSRPPGLSK SQVKLMDLED CALWEGKPRT YITEERADVS LTTLLTAQAS LKTKPIHTII RKRAPPCNND FCRLGCVCSS LALEKRQPAH CRRPDCMFGC TCLKRKVVLV KGGSKTKHFQ RKAAHRDPVF YDTLGEEARE EEEGIREEEE QLKEKKKRKK LEYTICETEP EQPVRHYPLW VKVEGEVDPE PVYIPTPSVI EPMKPLLLPQ PEVLSPTVKG KLLTGIKSPR SYTPKPNPVI REEDKDPVYL YFESMMTCAR VRVYERKKED QRQPSSSSSP SPSFQQQTSC HSSPENHNNA KEPDSEQQPL KQLTCDLEDD SDKLQEKSWK SSCNEGESSS TSYMHQRSPG GPTKLIEIIS DCNWEEDRNK ILSILSQHIN SNMPQSLKVG SFIIELASQR KSRGEKNPPV YSSRVKISMP SCQDQDDMAE KSGSETPDGP LSPGKMEDIS PVQTDALDSV RERLHGGKGL PFYAGLSPAG KLVAYKRKPS SSTSGLIQVA SNAKVAASRK PRTLLPSTSN SKMASSSGTA TNRPGKNLKA FVPAKRPIAA RPSPGGVFTQ FVMSKVGALQ QKIPGVSTPQ TLAGTQKFSI RPSPVMVVTP VVSSEPVQVC SPVTAAVTTT TPQVFLENTT AVTPMTAISD VETKETTYSS GATTTGVVEV SETNTSTSVT STQSTATVNL TKTTGITTPV ASVAFPKSLV ASPSTITLPV ASTASTSLVV VTAAASSSMV TTPTSSLGSV PIILSGINGS PPVSQRPENA AQIPVATPQV SPNTVKRAGP RLLLIPVQQG SPTLRPVSNT QLQGHRMVLQ PVRSPSGMNL FRHPNGQIVQ LLPLHQLRGS NTQPNLQPVM FRNPGSVMGI RLPAPSKPSE TPPSSTSSSA FSVMNPVIQA VGSSSAVNVI TQAPSLLSSG ASFVSQAGTL TLRISPPEPQ SFASKTGSET KITYSSGGQP VGTASLIPLQ SGSFALLQLP GQKPVPSSIL QHVASLQMKR ESQNPDQKDE TNSIKREQET KKVLQSEGEA VDPEANVIKQ NSGAATSEET LNDSLEDRGD HLDEECLPEE GCATVKPSEH SCITGSHTDQ DYKDVNEEYG ARNRKSSKEK VAVLEVRTIS EKASNKTVQN LSKVQHQKLG DVKVEQQKGF DNPEENSSEF PVTFKEESKF ELSGSKVMEQ QSNLQPEAKE KECGDSLEKD RERWRKHLKG PLTRKCVGAS QECKKEADEQ LIKETKTCQE NSDVFQQEQG ISDLLGKSGI TEDARVLKTE CDSWSRISNP SAFSIVPRRA AKSSRGNGHF QGHLLLPGEQ IQPKQEKKGG RSSADFTVLD LEEDDEDDNE KTDDSIDEIV DVVSDYQSEE VDDVEKNNCV EYIEDDEEHV DIETVEELSE EINVAHLKTT AAHTQSFKQP SCTHISADEK AAERSRKAPP IPLKLKPDYW SDKLQKEAEA FAYYRRTHTA NERRRRGEMR DLFEKLKITL GLLHSSKVSK SLILTRAFSE IQGLTDQADK LIGQKNLLTR KRNILIRKVS SLSGKTEEVV LKKLEYIYAK QQALEAQKRK KKMGSDEFDI SPRISKQQEG SSASSVDLGQ MFINNRRGKP LILSRKKDQA TENTSPLNTP HTSANLVMTP QGQLLTLKGP LFSGPVVAVS PDLLESDLKP QVAGSAVALP ENDDLFMMPR IVNVTSLATE GGLVDMGGSK YPHEVPDSKP SDHLKDTVRN EDNSLEDKGR ISSRGNRDGR VTLGPTQVFL ANKDSGYPQI VDVSNMQKAQ EFLPKKISGD MRGIQYKWKE SESRGERVKS KDSSFHKLKM KDLKDSSIEM ELRKVTSAIE EAALDSSELL TNMEDEDDTD ETLTSLLNEI AFLNQQLNDD SVGLAELPSS MDTEFPGDAR RAFISKVPPG SRATFQVEHL GTGLKELPDV QGESDSISPL LLHLEDDDFS ENEKQLAEPA SEPDVLKIVI DSEIKDSLLS NKKAIDGGKN TSGLPAEPES VSSPPTLHMK TGLENSNSTD TLWRPMPKLA PLGLKVANPS SDADGQSLKV MPCLAPIAAK VGSVGHKMNL TGNDQEGRES KVMPTLAPVV AKLGNSGASP SSAGK
Explore MAX gene-associated protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets